{"id":7186,"date":"2025-05-29T10:39:26","date_gmt":"2025-05-29T07:39:26","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=7186"},"modified":"2025-05-29T10:39:26","modified_gmt":"2025-05-29T07:39:26","slug":"obesity-app-may-enable-weight-loss-with-less-semaglutide","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/obesity-app-may-enable-weight-loss-with-less-semaglutide\/","title":{"rendered":"Obesity App May Enable Weight Loss With Less Semaglutide"},"content":{"rendered":"<div>Obesity App May Enable Weight Loss With Less Semaglutide<\/div>\n<div>Source: Medscape. May 15, 2025<\/div>\n<div>Presented at: European Congress on Obesity (ECO) 2025<\/div>\n<div><span> 1. Study Overview:<\/span><\/div>\n<div>The Embla digital obesity clinic showed an average 16.7% weight loss after 64 weeks using only ~1 mg\/week of semaglutide\u2014less than half the standard 2.4 mg\/week dose used in trials.<\/div>\n<div><span> 2. Intervention Approach:<\/span><\/div>\n<div>Embla combines personalized semaglutide dosing with intensive behavioral therapy via app-based coaching, diet and exercise plans, and psychological support (CBT, ACT), delivered by a multidisciplinary team.<\/div>\n<div><span> 3. Key Results:<\/span><\/div>\n<div><span> \u2022 Average semaglutide dose: 1.02 mg\/week<\/span><\/div>\n<div><span> \u2022 Weight loss: Women 17.6%, Men 13.4%<\/span><\/div>\n<div><span> \u2022 98% lost \u22655% weight; 82% lost \u226510%<\/span><\/div>\n<div><span> \u2022 Consistent results across BMI categories and semaglutide doses (as low as 0.25 mg\/week)<\/span><\/div>\n<div><span> \u2022 Higher engagement and weight loss observed in women<\/span><\/div>\n<div><span> 4. Real-World Context:<\/span><\/div>\n<div>Unlike RCTs, this real-world cohort maintained high weight loss with fewer dropouts than typical digital interventions.<\/div>\n<div><span> 5. Expert Commentary:<\/span><\/div>\n<div>Dr. Jason Halford emphasized the crucial role of behavioral support, suggesting that combining medication with behavioral change tools promotes sustainable results even after stopping the drug.<\/div>\n<div><span> 6. Safety &amp; Cost:<\/span><\/div>\n<div>Adverse events were monitored actively, with flexible dose adjustments based on tolerance.<\/div>\n<div>Embla subscription cost: \u20ac150\/month initially.<\/div>\n<div><span> 7. Funding &amp; Disclosures:<\/span><\/div>\n<div><span> \u2022 Study funded by Embla<\/span><\/div>\n<div><span> \u2022 Lead author Dr. Henrik Gudbergsen is CMO at Embla and holds stock<\/span><\/div>\n<div><span> \u2022 External experts disclosed consulting roles with various pharma companies<\/span><\/div>\n<div><\/div>\n<div>Conclusion:<\/div>\n<div>Digital platforms integrating behavioral support can enhance the effectiveness of semaglutide in weight loss while reducing required medication doses\u2014offering a promising and scalable real-world solution.<\/div>\n<div><\/div>\n<div><a href=\"https:\/\/www.medscape.com\/viewarticle\/obesity-app-may-enable-weight-loss-less-semaglutide-2025a1000c0d?utm_source=chatgpt.com\">https:\/\/www.medscape.com\/viewarticle\/obesity-app-may-enable-weight-loss-less-semaglutide-2025a1000c0d?utm_source=chatgpt.com<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Obesity App May Enable Weight Loss With Less Semaglutide Source: Medscape. May 15, 2025 Presented at: European Congress on Obesity (ECO) 2025 1. Study Overview: The Embla digital obesity clinic showed an average 16.7% weight loss after 64 weeks using only ~1 mg\/week of semaglutide\u2014less than half the standard 2.4 mg\/week dose used in trials. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7186","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=7186"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7186\/revisions"}],"predecessor-version":[{"id":7187,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7186\/revisions\/7187"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=7186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=7186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=7186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}